Glossary
Remission
Remission is a line on a score, and crossing that line is worth a great deal. It doesn't promise you'll feel well. Nobody says that part out loud at the visit where the word gets used.
What the research found.
One review pooled trials of following a protocol toward a combined target, and that got more people into remission than ordinary care did. The biggest trial reported 65 percent against 16 percent. Four more trials pointed in that direction by similar amounts.
Hock and colleagues, SN Comprehensive Clinical Medicine, 2021
One study asked 313 adults with inflammatory arthritis about their sleep, and their disease was mostly quiet or nearly quiet. Even so, 63.7 percent with rheumatoid arthritis slept badly. In psoriatic arthritis it was 61.5 percent and in axial spondyloarthritis 66.7 percent.
One study looked at 53 patients with adult-onset Still's disease whose activity was low or absent, against 53 matched healthy controls. Four things came out worse in the patients, which were quality of life, disability, tiredness, and pain. The abstract attaches no numbers to any of them.
One review pooled 71 studies in rheumatoid arthritis, where low mood and anxiety went with DAS28 remission at an odds ratio of 1.77. The true value sits somewhere from 1.36 to 2.29. Its authors report lower remission rates in the patients with that distress.
In polymyalgia rheumatica, the three-month change in vitamin D went with early remission at an odds ratio of 2.89, with the true value somewhere from 1.60 to 4.11. Two dose measures predicted nothing at all. Neither the prednisone dose nor the total steroid taken over time did.
Remission is a line, not a feeling
Remission in an inflammatory disease means one thing, which is that your measured activity has dropped below a set level. In rheumatoid arthritis that level sits on a combined score pulling together joint counts, a blood marker of inflammation, and your own overall rating. Crossing that line is a real achievement. It's also a statement about measurements rather than about how your week went.
That difference gets lost, because the word means so much more than that in ordinary speech. Told they're in remission, most people hear recovered. What the doctor means is smaller: the numbers that steer your treatment have come down far enough that stepping the treatment up is no longer called for.
Both things can be true at once, and they very often are. The score is genuinely low, the treatment is genuinely working, and the person sitting in the chair is genuinely still tired. Holding all three of those together gets a good deal easier once you know that the word describes a measurement and nothing else.
It isn't a cure, and the treatment usually stays
Most remission definitions sit perfectly well alongside staying on your medication, which surprises people who assume the word means finishing. In an inflammatory autoimmune disease the treatment holds the disease down rather than removing it. So remission and an ongoing prescription sit together without any contradiction between them.
The practical result is about stopping. Some people do cut down or come off treatment in remission, under supervision, with a plan for what to watch, and that's a very different thing from stopping because a score looked good. Autoimmune illnesses get managed rather than cured, and a page that blurred that would be doing you a disservice.
Raising the goal is still worth doing. If getting off one drug is what you want, say so at a visit, and your team then has something to plan toward. What it shouldn't turn into is a solo decision made on one number.
Aiming at a target works better than going by impression
The best evidence about remission isn't about the line itself. It's about aiming for one. One review pooled randomized trials where some patients followed a protocol toward a combined target, and more of them reached remission than under ordinary care, with the biggest trial reporting 65 percent against 16 percent.
Four more trials in that review pointed in that direction too, with differences running from about 13 to 22 percentage points. So one approach won, which was stepping treatment up until a set target is reached, against adjusting it by a doctor's judgment alone. That's a strong argument for having a number and for following it.
It isn't an argument that any one number is correct. What the review shows is the value of the method rather than the rightness of the line, and this page prints no line for any disease. We hold no source for the published cut-offs, and a figure quoted from memory is a figure a reader will act on, so none is printed here.
The finding that remission doesn't fix everything
Two studies in our sources measure something odd, which is the distance between a controlled score and a life. Read both of them if you have ever felt unimpressed by your own remission and then felt bad about that. The first looked at sleep, asking 313 adults with inflammatory arthritis whose disease was mostly quiet or nearly quiet, and 63.7 percent with rheumatoid arthritis still slept badly, with 61.5 percent in psoriatic arthritis and 66.7 percent in axial spondyloarthritis.
The second study looked wider. It took 53 patients with adult-onset Still's disease whose activity was low or absent and set them against 53 matched healthy controls, and four things came out worse in the patients: quality of life, disability, tiredness, and pain. Our record for that study notes something unusual, which is that the abstract reports no numbers at all, so this page gives the direction and attaches no figures to it.
Both studies looked at people at one moment, so they describe things happening together rather than showing one causing the other. What they do settle is smaller and useful. Lasting symptoms in remission are common and written down, so treating those symptoms as their own problem gets you further than treating them as proof the remission isn't real.
What has been linked to reaching it
Two findings in our sources travel with remission, and neither one is a treatment for it. Both only watched what happened, so both are worth discussing and neither is worth acting on alone. Reading either as an instruction would go past what it shows.
The first is mood. One review pooled 71 studies in rheumatoid arthritis, where low mood and anxiety went with DAS28 remission at an odds ratio of 1.77, with the true value somewhere from 1.36 to 2.29. Its authors report three things in those patients, which are lower remission rates, more disability, and higher death rates. Data that only watches can't separate distress making the disease worse from the disease causing the distress.
The second is vitamin D in polymyalgia rheumatica. One study looked back at records, where the three-month change in vitamin D went with early remission at an odds ratio of 2.89, from 1.60 to 4.11. Two dose measures predicted nothing, neither the prednisone dose nor the total steroid taken over time. So that's a link inside a treated group, and people who respond well to treatment may differ in other ways, absorbing vitamin D better, storing it better, or taking it more reliably.
Common misconceptions.
Myth. Remission means my disease is gone.
Reality. It means your measured activity has dropped below a set line, which is a different claim. The treatment that got you there is usually what holds you there, and most remission definitions sit perfectly well alongside staying on your medication. So the word comes up beside a conversation about continuing rather than beside one about stopping. Stop without a plan and you learn that difference the hard way.
Myth. If I'm in remission I should feel well.
Reality. Very often people don't, and the numbers behind that are blunt. About two in three adults with inflammatory arthritis slept badly while their disease was in remission or barely active. In adult-onset Still's disease, where activity was low or absent, four things came out worse than in matched controls: quality of life, disability, tiredness, and pain. So feeling unwell in remission is common rather than a sign you're making it up.
Myth. Still feeling tired means the remission isn't real.
Reality. It usually means remission measures less than you thought it did. The scores count joints, blood markers, and set clinical signs, while tiredness and sleep sit outside most of them. Both those studies found lasting symptoms in people whose disease activity was genuinely low, so treat the remaining symptoms as their own problem rather than as proof the score is wrong.
Myth. There's one definition of remission.
Reality. There isn't, and the figure you get quoted depends on which one somebody used. Different combined scores set different lines, so a trial reports its remission rate against one definition while another trial may use a different one. This site holds no source comparing the definitions, so how far the rate moves with the definition is something nobody here can tell you. That's a real hole on a page about this word.
Related terms.
- DAS28, the composite score most remission definitions in rheumatoid arthritis are built on.
- Flare, which is the state remission is defined against.
- Inflammation, and the difference between the kind you can measure and the kind you have.
- Polymyalgia rheumatica and blood tests, for the vitamin D finding in full.
Questions patients ask.
Is remission a cure?
No, and that difference is the most useful thing on this page. Remission describes measured disease activity below a line, at one moment in time, and it usually describes that while treatment continues. A cure would mean two things together, which are that the disease is gone and that you no longer need the treatment. Autoimmune illnesses generally get managed rather than cured, which is why the words stay careful here.
Can I stop my medication in remission?
That's a question for the team prescribing it, and the reason is worth knowing. Your treatment is usually part of why you're in remission in the first place. Some people do cut down or stop under supervision, and doing it without a plan is how people learn the difference the hard way. So raise it as a goal at a visit, because that's fair, and doing it alone isn't.
Why do I still feel tired in remission?
Because the scores that set remission mostly leave out tiredness and sleep. One study asked 313 adults with inflammatory arthritis about sleep, and about two in three of them slept badly while their disease was in remission or barely active. A second study looked at Still's disease, where activity was low or absent and tiredness and quality of life still came out worse than in healthy matched controls. So that's a written-down finding rather than you getting something wrong.
What score is used to define it?
It depends on the disease and on the study, and this site holds no source comparing the definitions. In rheumatoid arthritis the usual basis is a combined score pulling together joint counts, a blood marker of inflammation, and your own overall rating. The line moves between definitions, though, so a quoted remission rate means little until you know which definition produced it. Asking is a fair question.
Does treating to a target help?
Yes, and it's some of the better evidence in this whole area. One review pooled randomized trials where following a protocol toward a combined target beat ordinary care, and more people reached remission that way, with the biggest trial reporting 65 percent against 16 percent. So that backs having a target and stepping treatment up until you reach it. It doesn't say that any one line is the right line.
Does my mood affect my chance of remission?
One review pooled 71 studies, where low mood and anxiety went with DAS28 remission at an odds ratio of 1.77. Its authors report three things in those patients: lower remission rates, more disability, and higher death rates. Those studies only watched what happened, though, so they can't separate distress making the disease worse from the disease causing it in the first place. Either way, it belongs in the rheumatology conversation.
Can anything I do outside medication predict remission?
One study looked back at records in polymyalgia rheumatica, where the three-month change in vitamin D went with early remission at an odds ratio of 2.89 while two dose measures predicted nothing. So that's a link found inside a treated group rather than evidence that taking vitamin D brings remission. It's interesting enough to discuss and not enough to act on by itself.
References.
- Hock E; Martyn-St James M; Wailoo A et al. Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. SN Comprehensive Clinical Medicine. 2021;3:838-854. 10.1007/s42399-021-00727-4Systematic review of randomised controlled trials
- Polak D; Kolasińska M; Wilk M et al. Sleep disorders in RA, axSpA and PsA are common despite good disease activity control—direct comparison of sleep quality and its risk factors using MDHAQ and PSQI. Clinical Rheumatology. 2026;45:957-965. 10.1007/s10067-025-07892-0Cross-sectional study of 313 adults from the PolNorRHEUMA registry: RA n = 129
- Ruscitti P; Rozza G; Di Muzio C et al. Assessment of health-related quality of life in patients with adult onset Still disease: Results from a multicentre cross-sectional study. Medicine. 2022;101:e29540. 10.1097/MD.0000000000029540Multicentre cross-sectional case-control study
- Sweeney M; Adas M; Cope A et al. Longitudinal effects of affective distress on disease outcomes in rheumatoid arthritis: a meta-analysis and systematic review. Rheumatology International. 2024;44:1421-1433. 10.1007/s00296-024-05574-9Systematic review and meta-analysis of longitudinal observational studies
- Hysa E; Balito S; Davoli G et al. Vitamin D Status and Response to Supplementation as Predictive Factors for Early Remission in Polymyalgia Rheumatica: A Retrospective Longitudinal Investigation. Nutrients. 2025;17:2839. 10.3390/nu17172839Retrospective observational case-control study with a longitudinal subgroup
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.